tetradecanoylphorbol acetate has been researched along with baricitinib in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (50.00) | 24.3611 |
| 2020's | 1 (50.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mitchell, TS; Moots, RJ; Wright, HL | 1 |
| Evan Prince, S; Hiraganahalli Bhaskarmurthy, D | 1 |
2 other study(ies) available for tetradecanoylphorbol acetate and baricitinib
| Article | Year |
|---|---|
Janus kinase inhibitors prevent migration of rheumatoid arthritis neutrophils towards interleukin-8, but do not inhibit priming of the respiratory burst or reactive oxygen species production.
Topics: Adult; Aged; Aged, 80 and over; Arthritis, Rheumatoid; Azetidines; Case-Control Studies; Cell Movement; Cells, Cultured; Female; Granulocyte-Macrophage Colony-Stimulating Factor; Humans; Interleukin-8; Janus Kinases; Male; Middle Aged; Neutrophils; Piperidines; Protein Kinase Inhibitors; Purines; Pyrazoles; Pyrimidines; Pyrroles; Reactive Oxygen Species; Respiratory Burst; Sulfonamides; Tetradecanoylphorbol Acetate; United Kingdom | 2017 |
Effect of Baricitinib on TPA-induced psoriasis like skin inflammation.
Topics: Administration, Topical; Animals; Azetidines; Carcinogens; Inflammation; Mice; Mice, Inbred BALB C; Psoriasis; Purines; Pyrazoles; Skin; Sulfonamides; Tetradecanoylphorbol Acetate | 2021 |